Heartseed（ハートシード）株式会社はiPS細胞による心臓の再生医療を実現します。慶應義塾大学医学部循環器内科福田恵一教授の技術を用いて心不全の治療を目指す革新的な大学発ベンチャーです。
Location: Japan, Tokyo
Total raised: $77.33M
Investors 2
| Date | Name | Website |
| 03.04.2024 | Medical In... | medicalinc... |
| - | Angel Brid... | angelbridg... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 25.05.2023 | Series D | $14.33M | UTokyo Inn... |
| 11.06.2021 | Series C | $37M | - |
| 22.11.2019 | Series B | $26M | - |
Mentions in press and media 10
| Date | Title | Description |
| 02.11.2023 | Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine | PALO ALTO, Calif., Nov. 2, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. ... |
| 25.05.2023 | Heartseed Raises 2 Billion JPY in Series D Funding | Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), raised 2 Billion JPY in Series D funding. The round, which brought the total amount to 10.2 Billion JPY (approx. $74M), saw... |
| 29.03.2022 | Heartseed Inc. Heartseed decides to adopt “Innovation TOKYO Project that opens up the future” | Heartseed Inc. Heartseed decides to adopt “Innovation TOKYO Project that opens up the future” It was adopted as a subsidy project of up to 300 million yen implemented by the Tokyo Metropolitan Government. Heartseed develops iPS cell-derived... |
| 11.06.2021 | Heartseed Raises $37M in Series C Funding | Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), raised 4 Billion-yen (approx. $37M) in Series C funding. The round brought its total financial backing to 8.2 Billion yen (... |
| 11.06.2021 | Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure | Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 B... |
| 26.11.2019 | Daily funding roundup - November 25th, 2019 | Osome landed $3M; Rad AI raised $4M; Heartseed secured $26M; v2food picks up $35M Osome: Osome is a Fintech-as-a-service for entrepreneurs platform. Osome has raised $3 million financing led by Target Global, with participation from Phystec... |
| 22.11.2019 | Heartseed Secures $26M in Series B Funding | Heartseed, a Tokyo, Japan-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), raised 2.8 Billion-yen (approx. $26m) in Series B funding. Backers in this round, which brought total fina... |
| 22.11.2019 | Top tech startup news for today, Friday, November 22, 2019 – Tesla, AirBnB, Capitolis, Google, Next Coast Ventures | Good morning! Below are some of the top tech startup news for today, Friday, November 22, 2019. Tesla claimed its pickup truck was ‘bulletproof’ — then smashed its windows with a metal ball. You are probably tired of hearing about Tesla’s ... |
| 22.11.2019 | Tokyo tech startup Heartseed secures $26M Series B to accelerate development of iPSC-derived regenerative medicine for heart failure | Cardiovascular disease is the number one killer worldwide. Enter Heartseed, a developing PSC-derived cardiomyocytes for the treatment of heart failure. Heartseed is changing the world using regenerative medicine. Its breakthrough technology... |
| - | Heartseed | - |